Tofacitinib in Ulcerative Colitis-evolving Efficacy and Safety

Tiwari, Avinash; Ashraf, Aadil; Bharali, Pankaj

doi:10.1097/mcg.0000000000001823

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tofacitinib is approved for managing moderate-to-severe ulcerative colitis in patients either resistant to conventional treatment or bDMARDs (34). Polyarticular juvenile idiopathic arthritis, Sistemic juvenile idiopathic arthritis, Sjogren's syndrome, systemic sclerosis, Takayasu arteritis, atopic dermatitis, alopecia areata, psoriasis, polymyalgia rheumatica, Crohn's disease, pouchitis, cutaneous lupus erythematosus, kidney transplant, and COVID-19 are other conditions in which tofacitinib is being tried at different phase trials (4).…”

Section: Use In Other Diseasesmentioning

confidence: 99%

Tofacitinib: Current Considerations in the Management of Immune Inflammatory Disorders

Erden¹

2023

qrheumatol

View full text Add to dashboard Cite

INVITED REVIEWTofacitinib, the first member of targeted-synthetic disease-modifying antirheumatic drugs, is an oral inhibitor of Janus kinases (JAKs), preferentially JAK-1 and 3. It is an analog of adenosine triphosphate and inhibits several pro-inflammatory cytokines and pathways. Tofacitinib is rapidly absorbed and eliminated mainly via the liver. The efficacy of tofacitinib has been studied extensively in patients with RA patients with different clinical scenarios. Now, tofacitinib is approved in several countries with the indications of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polyarticular and systemic juvenile idiopathic arthritis, and ulcerative colitis. Also, studies to assess the efficacy of tofacitinib in patients with several different indications are under consideration. Neutropenia, anemia, elevation of transaminase levels, hyperlipidemia, and increased risk of infections with several causes are well-known side effects. However, recent data from the ORAL Surveillance study shed light on the risk of cardiovascular events and malignancy. In that study, patients with RA over 50 years with at least 1 cardiovascular risk factor were randomized to anti-tumor necrosis factors or tofacitinib; revealing and increased cardiovascular event risk and malignancy (especially lung cancer and lymphoma) in the tofacitinib arm. Although post hoc analysis of the data set suggested a possible link between the history of cardiovascular disease and both cardiovascular and malignancy end-points, FDA, and EMA announced black-box warnings for all JAK inhibitors covering all indications. Obviously, JAK inhibitors, the game changers of the last decade, need further evaluation, especially regarding safety issues.

show abstract

Section: Use In Other Diseasesmentioning

confidence: 99%

Tofacitinib: Current Considerations in the Management of Immune Inflammatory Disorders

Erden¹

2023

qrheumatol

View full text Add to dashboard Cite

show abstract

Tofacitinib in Ulcerative Colitis-evolving Efficacy and Safety

Cited by 1 publication

References 9 publications

Tofacitinib: Current Considerations in the Management of Immune Inflammatory Disorders

Tofacitinib: Current Considerations in the Management of Immune Inflammatory Disorders

Contact Info

Product

Resources

About